Health & Medicinearticle2026-11-16

Solitary plasmacytoma of bone (SPB): observations from a randomized phase III trial that evaluated the additional of adjuvant systemic treatment to zoledronic acid (ZA) after definitive radiation (alliance A061402)

Open access0 citations

Abstract

Solitary plasmacytoma of bone (SPB) is a localized tumor in the bone comprised of clonal plasma cells in the absence of other diagnostic features of multiple myeloma (MM), though patients may present with <10% clonal plasma cells in the bone marrow [ 1 ]. Most patients with SPB eventually develop overt MM, and numerous factors are associated with a shorter time to progression to active MM, including the presence of high-risk cytogenetics, abnormal serum free light chain ratio, minimal marrow involvement, and high-grade angiogenesis within the plasmacytoma [ 2 , 3 , 4 , 5 ].

// Source

View paper (DOI)Open access versionOpenAlexBlood Cancer JournalPublished 2026-11-16

Authors: Douglas Weston Sborov, Anuj Mahindra, Vera Suman, Elisabet Esteve Manasanch, Prashant Kapoor, Tibor Kovacsovics, Cesar Rodriguez, Benjamin Marshall Parsons, Jose Eugenio Najera, Lyle Goldman, Destin Carlisle, Yujia Wen, Shira Naomi Dinner, Ilene A Galinsky, LeAnne Kennedy, James Omel, Philip McCarthy, Saad Z. Usmani, Paul Richardson

Institutions: University of Chicago, Icahn School of Medicine at Mount Sinai, Harvard University, The University of Texas MD Anderson Cancer Center, University of Utah, Mayo Clinic in Arizona, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center, Mayo Clinic, City of Hope, Atrium Health Wake Forest Baptist, Huntsman Cancer Institute, Alliance for Clinical Trials in Oncology, Ascension, Tisch Cancer Institute, Scripps MD Anderson Cancer Center, Alliance Data (United States), Gundersen Health System, Cancer Centers of Southwest Oklahoma